| Literature DB >> 27980499 |
Ajmol Ali1, Jemma O'Donnell1, Andrew Foskett1, Kay Rutherfurd-Markwick2.
Abstract
BACKGROUND: The aim of this study was to examine the influence of caffeine supplementation on knee flexor and knee extensor strength before, during and after intermittent running exercise in female team-sport players taking oral contraceptive steroids (OCS).Entities:
Keywords: Knee extensors; Knee flexors; Muscle function; Pharmacological ergogenic aid; Supplementation
Mesh:
Substances:
Year: 2016 PMID: 27980499 PMCID: PMC5139084 DOI: 10.1186/s12970-016-0157-4
Source DB: PubMed Journal: J Int Soc Sports Nutr ISSN: 1550-2783 Impact factor: 5.150
Fig. 1Schematic representation of protocol. Intermittent exercise was carried out in six 15-min blocks 60 min after ingestion of caffeine (CAFF) or placebo (PLA). Plasma concentrations of insulin and free fatty acids were assessed following blood sampling (black arrows), leg muscle strength and power were determined using an isokinetic dynamometer (eccentric and concentric knee extensors and flexors, white arrows) and counter movement jump (CMJ) height was used as a concurrent measure of power (hashed arrows). Final measurements were taken the following day, approximately 12 h after the exercise protocol
Fig. 2Mean (± SD) eccentric knee flexor (a and c) and extensor (b and d) strength (a and b) and power (c and d) parameters for caffeine (CAFF) and placebo (PLA) trials before, during and after the 90-min intermittent exercise protocol. * Significantly higher in CAFF trial (P < 0.05; n = 10)
Mean (± SD) concentric knee flexor and extensor strength and power parameters for caffeine (CAFF) and placebo (PLA) trials before, during and after the 90-min intermittent exercise protocol (n = 10)
| Sample time | Cohen’s d (Trial Mean) | Statistical significance ( | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Pre | Mid | Post | ~12 h post | Trial Mean | Treatment | Time | Treatment x Time | ||
| Average torque (Nm) | |||||||||
|
| |||||||||
| PLA | 79.7 ± 21.2 | 77.9 ± 23.4 | 77.1 ± 20.8 | 76.0 ± 18.8 | 77.6 ± 20.3 | 0.11 | 0.327 | 0.920 | 0.222 |
| CAFF | 75.9 ± 19.8 | 80.6 ± 17.3 | 80.2 ± 20.1 | 82.4 ± 19.1 | 79.8 ± 18.5 | ||||
|
| |||||||||
| PLA | 104.4 ± 34.6 | 105.0 ± 35.7 | 111.8 ± 43.2 | 102.6 ± 32.7 | 106.0 ± 35.5 | 0.29 | 0.053 | 0.678 | 0.257 |
| CAFF | 112.6 ± 45.3 | 115.7 ± 33.7 | 114.4 ± 32.3 | 124.2 ± 43.2 | 116.8 ± 37.8 | ||||
| Average power (Watts) | |||||||||
|
| |||||||||
| PLA | 25.7 ± 7.5 | 23.7 ± 6.5 | 24.0 ± 7.1 | 24.6 ± 6.2 | 24.5 ± 6.6 | 0.11 | 0.274 | 0.076 | 0.385 |
| CAFF | 24.8 ± 7.1 | 24.5 ± 7.4 | 24.5 ± 5.8 | 26.9 ± 6.8 | 25.2 ± 6.6 | ||||
|
| |||||||||
| PLA | 24.3 ± 8.7 | 23.8 ± 9.0 | 25.5 ± 9.2 | 23.5 ± 7.6 | 24.3 ± 8.4 | 0.23 | 0.151 | 0.372 | 0.069 |
| CAFF | 23.1 ± 8.0 | 26.7 ± 8.0 | 27.0 ± 8.1 | 28.2 ± 9.6 | 26.2 ± 8.3 | ||||
Cohen’s d values are based on the corresponding trial mean
Mean (± SD) isometric knee flexor and extensor strength parameters for caffeine (CAFF) and placebo (PLA) trials before, during and after the 90-min intermittent exercise protocol (n = 10)
| Average torque (Nm) | Sample time | Cohen’s d (Trial Mean) | Statistical significance ( | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Pre | Mid | Post | ~ 12 h post | Trial Mean | Treatment | Time | Treatment x Time | ||
|
| |||||||||
| PLA | 77.6 ± 18.6 | 77.0 ± 16.9 | 76.3 ± 17.5 | 76.1 ± 19.1 | 76.7 ± 17.3 | 0.18 | 0.143 | 0.981 | 0.841 |
| CAFF | 77.9 ± 18.3 | 79.9 ± 24.9 | 81.7 ± 17.0 | 80.8 ± 22.4 | 80.1 ± 20.1 | ||||
|
| |||||||||
| PLA | 157.4 ± 40.8 | 155.3 ± 38.9 | 156.1 ± 35.1 | 154.2 ± 42.3 | 155.7 ± 37.8 | 0.04 | 0.837 | 0.845 | 0.657 |
| CAFF | 153.6 ± 47.7 | 151.8 ± 30.0 | 159.9 ± 44.0 | 164.6 ± 48.9 | 157.4 ± 42.0 | ||||
Cohen’s d values are based on the corresponding trial mean
Mean (± SD) counter-movement jump (CMJ) and estimated power parameters for caffeine (CAFF) and placebo (PLA) trials before, during and after the 90-min intermittent exercise protocol (n = 10)
| Sample time | Cohen’s d (Trial Mean) | Statistical significance ( | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pre | Block 1 | Block 2 | Block 3 | Block 4 | Block 5 | Block 6 | ~12 h post | Trial Mean | Treatment | Time | Treatment x Time | ||
|
| |||||||||||||
| PLA | 38.4 | 40.8 | 40.5 | 40.7 | 41.6 | 39.9 | 39.4 | 36.2 | 39.7 | 0.08 | 0.582 | <0.001 | 0.951 |
| ± 4.4 | ± 5.8 | ± 5.7 | ± 6.3 | ± 7.0 | ± 5.4 | ± 6.0 | ± 4.5 | ± 5.7 | |||||
| CAFF | 38.5 | 41.6 | 40.8 | 41.0 | 41.0 | 39.8 | 40.5 | 37.2 | 40.1 | ||||
| ± 5.5 | ± 4.7 | ± 4.1 | ± 5.4 | ± 4.3 | ± 4.0 | ± 4.2 | ± 4.9 | ± 4.7 | |||||
|
| |||||||||||||
| PLA | 2976.1 | 3123.0 | 3105.7 | 3116.4 | 3168.9 | 3067.1 | 3039.4 | 2843.5 | 3055.0 | 0.09 | 0.391 | <0.001 | 0.950 |
| ± 339.2 | ± 412.0 | ± 414.2 | ± 452.5 | ± 477.6 | ± 363.1 | ± 463.9 | ± 332.2 | ± 403.7 | |||||
| CAFF | 2996.2 | 3182.7 | 3136.5 | 3144.2 | 3148.8 | 3075.2 | 3116.7 | 2914.5 | 3089.3 | ||||
| ± 377.8 | ± 354.1 | ± 305.9 | ± 377.2 | ± 314.8 | ± 278.5 | ± 321.0 | ± 372.8 | ± 390.8 | |||||
Cohen’s d values are based on the corresponding trial mean
Fig. 3Mean (± SD) plasma concentrations of (a) insulin (μU·mL−1) and (b) free fatty acids (FFA; mmol·mL− 1) for caffeine (CAFF) and placebo (PLA) trials before, during and after the 90-min intermittent exercise protocol. * Significantly higher in CAFF trial (P < 0.05; n = 10)